NASDAQ$SVRA
Savara Inc · Q3 2025 earnings
Q3 2025 earnings · · Before market open · Investor relations
Briefing
Savara reported a net loss of $29.6 million in Q3 2025 as it continued advancing its lead program, MOLBREEVI, toward regulatory milestones.
Savara posted a larger net loss in Q3 2025 compared to the previous year due to increased R&D and G&A expenses, as the company progresses its MOLBREEVI development and prepares for commercialization.
- Net loss widened to $29.6 million from $24.2 million in Q3 2024
- EPS came in at -$0.14 per share
- Cash and short-term investments totaled $124.4 million at quarter-end
- Significant investments made to support MOLBREEVI resubmission and commercial readiness
Headline financials
Revenue & EPS history
Savara · Revenue · Quarterly
$0
Forward guidance
Savara remains on track to resubmit the BLA for MOLBREEVI in December 2025 and expects MAA submissions in early 2026, while recent financings have extended its cash runway to support commercialization.
Tailwinds
- On track to resubmit MOLBREEVI BLA in December 2025
- Expecting MAA submissions in EU and UK in Q1 2026
- Recent equity raise added $140M to the balance sheet
- Presented supportive IMPALA-2 efficacy data
- Announced $75M royalty funding agreement for MOLBREEVI
Headwinds
- No approved therapy yet for autoimmune PAP
- Still in pre-commercialization stage
- Net loss increased year-over-year
- Higher G&A costs impacting profitability
- Pending regulatory approvals introduce uncertainty
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2025
-1.1%
Avg return
Earnings day
+0.8%
Avg return
5 days after
+7.6%
Avg return
30 days after
35%
13 / 37 earnings
Positive
+12.5%
Q3 2018
Best reaction
-20.1%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.8% | -1.8% | — | |
| Q4 2025 | -0.8% | +3.4% | -3.0% | |
| Q3 2025 | -4.9% | -3.0% | +59.8% | |
| Q2 2025 | +5.5% | +18.2% | +38.0% | |
| Q1 2025 | +9.9% | +23.7% | +13.9% | |
| Q4 2024 | +4.7% | +8.3% | +14.4% | |
| Q3 2024 | -20.1% | -26.8% | -17.7% | |
| Q2 2024 | +4.0% | +9.3% | +8.5% | |
| Q1 2024 | -6.6% | -3.6% | -20.6% | |
| Q4 2023 | -2.2% | -9.2% | -11.8% | |
| Q3 2023 | -6.2% | -0.5% | +12.4% | |
| Q2 2023 | +4.3% | +3.8% | -0.8% | |
| Q1 2023 | +8.5% | +31.7% | +60.8% | |
| Q4 2022 | -3.9% | -15.8% | -7.4% | |
| Q3 2022 | +5.4% | +18.0% | +42.3% | |
| Q2 2022 | +3.0% | -0.6% | -10.8% | |
| Q1 2022 | +3.6% | +20.0% | +28.2% | |
| Q4 2021 | +5.6% | +3.2% | -4.8% | |
| Q3 2021 | -1.7% | -3.4% | -10.3% | |
| Q2 2021 | -3.3% | -4.1% | +17.9% | |
| Q1 2021 | +1.3% | +5.2% | +18.8% | |
| Q4 2020 | -13.6% | -3.8% | +6.0% | |
| Q3 2020 | -3.7% | +3.7% | +32.1% | |
| Q2 2020 | +0.0% | -8.0% | -41.0% | |
| Q1 2020 | -2.5% | +2.1% | +0.8% | |
| Q4 2019 | -2.5% | +0.4% | -10.2% | |
| Q3 2019 | -7.6% | -15.8% | +22.1% | |
| Q2 2019 | -6.5% | -3.7% | -1.6% | |
| Q1 2019 | +2.0% | +0.5% | -7.8% | |
| Q4 2018 | -4.2% | -2.7% | +11.5% | |
| Q3 2018 | +12.5% | +2.9% | -20.3% | |
| Q2 2018 | -2.6% | -7.6% | -2.0% | |
| Q1 2018 | -5.8% | -4.7% | +14.9% | |
| Q4 2017 | -4.5% | -1.0% | -12.4% | |
| Q3 2017 | -4.3% | +4.4% | +49.3% | |
| Q2 2017 | -3.7% | -4.2% | +13.3% | |
| Q1 2017 | -0.5% | -7.4% | -7.9% | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro